<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient with apical hypertrophic cardiomyopahty (AHCM) complicated by a cardiogenic <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A 56-year-old man was admitted to our hospital because of a <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>He had been diagnosed as having AHCM at the age of 39 years </plain></SENT>
<SENT sid="3" pm="."><plain>The intravenous administration of <z:chebi fb="5" ids="28304">heparin</z:chebi> was immediately started; however, he developed a <z:mp ids='MP_0000746'>weakness</z:mp> in his right fingers on the second day </plain></SENT>
<SENT sid="4" pm="."><plain>A brain MRI examination showed multiple small infarctions in the cortex of the left frontal and temporal lobes </plain></SENT>
<SENT sid="5" pm="."><plain>Transthoracic echocardiography revealed the hypokinetic movement of the myocardium and a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in the apex </plain></SENT>
<SENT sid="6" pm="."><plain>We suspected that the hypertrophic apex had become dilated, causing the formation of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>He then developed a cardiogenic <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in the apex disappeared after the continuous administration of <z:chebi fb="5" ids="28304">heparin</z:chebi> intravenously </plain></SENT>
<SENT sid="9" pm="."><plain>Here, we emphasize that patients with AHCM in the <z:mpath ids='MPATH_66'>dilatation</z:mpath> phase must receive <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy to prevent cardiogenic <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
</text></document>